{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:58:42Z","timestamp":1789441122518,"version":"build-2803163510"},"reference-count":64,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Radiation therapy is part of the therapeutic arsenal for breast cancer, whether it is adjuvant treatment after lumpectomy or radical mastectomy, or it is used as a palliative option in the case of metastatic or recurrent disease. Significant advances in diagnostic and therapeutic stratification of breast cancers have significantly prolonged survival, even in the metastatic stage. Exposure of patients during the course of the disease in a multidisciplinary therapeutic approach including chemotherapy, hormone therapy, targeted anti-HER therapies or CDK4\/6 inhibitors had led to improved survival but with the price of additional toxicity. Among them, hypothyroidism is a well-known consequence of external radiation therapy, especially in the case of cervical region irradiation, including supraclavicular and infra-clavicular nodal levels. In this situation, the thyroid gland is considered as an organ at risk (OAR) and receives a significant dose of radiation. Subclinical hypothyroidism is a common endocrine disorder characterized by elevated TSH levels with normal levels of FT4 (free T4) and FT3 (free T3), and as a late effect, primary hypothyroidism is one of the late effects that significantly affects the quality of life for patients with breast cancer receiving multimodal treatment. Hypothyroidism has a significant impact on quality of life, most often occurring as late clinical toxicity, secondary to thyroid irradiation at doses between 30 and 70 Gy. Dose-volume parameters of irradiation, gland function at the beginning of the treatment and associated systemic therapies may be factors that alter thyroid radio-sensitivity and affect thyroid gland tolerance. In the case of head and neck tumor pathology, in which doses of &gt;50 Gy are routinely used, the thyroid gland is generally considered as an OAR, the rate of radio-induced hypothyroidism being estimated at rates of between 20% and 52%. For breast cancer, the thyroid is often neglected in terms of dosimetry protection, the rate of late dysfunction being 6\u201321%.<\/jats:p>","DOI":"10.3390\/jcm10235503","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T01:43:22Z","timestamp":1638323002000},"page":"5503","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An Underestimated Toxicity Radiation-Induced Hypothyroidism in Patients Multimodally Treated for Breast Cancer"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-8008","authenticated-orcid":false,"given":"Camil Ciprian","family":"Mire\u0219tean","sequence":"first","affiliation":[{"name":"Department of Oncology and Radiotherapy, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania"},{"name":"Department of Surgery, Railways Clinical Hospital Iasi, 700506 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana Irina","family":"Iancu","sequence":"additional","affiliation":[{"name":"Oral Pathology Department, Faculty of Dental Medicine, \u201cGr. T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Department of Clinical Laboratory, \u201cSt. Spiridon\u201d Emergency Universitary Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drago\u0219 Petru Teodor","family":"Iancu","sequence":"additional","affiliation":[{"name":"Oncology and Radiotherapy Department, Faculty of Medicine, \u201cGr. T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Department of Radiation Oncology, Regional Institute of Oncology, 700483 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1758835918786451","DOI":"10.1177\/1758835918786451","article-title":"CDK4\/6 inhibition in breast cancer: Current practice and future directions","volume":"10","author":"Pernas","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/2278-330X.130445","article-title":"Late effects of cancer treatment in breast cancer survivors","volume":"3","author":"Agrawal","year":"2014","journal-title":"South Asian J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/0360-3016(95)00019-U","article-title":"Thyroid abnormalities after therapeutic external radiation","volume":"31","author":"Hancock","year":"1995","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ctrv.2003.12.003","article-title":"Radiotherapy-induced thyroid disorders","volume":"30","author":"Alterio","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.ijrobp.2007.01.029","article-title":"Primary and Central Hypothyroidism after Radiotherapy for Head-and-Neck Tumors","volume":"68","author":"Bhandare","year":"2007","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2011.03.002","article-title":"Radiation-induced hypothyroidism in head and neck cancer patients: A systematic review","volume":"99","author":"Boomsma","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/0021-9681(61)90022-4","article-title":"Occult hypothyroidism and \u201cmetabolic insufficiency\u201d","volume":"14","author":"Jefferies","year":"1961","journal-title":"J. Chronic Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2020.09.003","article-title":"NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer","volume":"154","author":"Huang","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ijrobp.2010.09.054","article-title":"Thyroid V30 Predicts Radiation-Induced Hypothyroidism in Patients Treated With Sequential Chemo-Radiotherapy for Hodgkin\u2019s Lymphoma","volume":"82","author":"Cella","year":"2012","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.coc.0000217831.23820.85","article-title":"Hypothyroidism When the Thyroid Is Included Only in the Low Neck Field during Head and Neck Radiotherapy","volume":"29","author":"Norris","year":"2006","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/1097-0142(20011201)92:11<2892::AID-CNCR10134>3.0.CO;2-T","article-title":"Hypothyroidism: A frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma","volume":"92","author":"Mercado","year":"2001","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lin, C.-L., Wu, S.-Y., Huang, W.-T., Feng, Y.-H., Yiu, C.-Y., Chiang, W.-F., Ho, S.-Y., and Lin, S.-H. (2019). Subsequent thyroid disorders associated with treatment strategy in head and neck cancer patients: A nationwide cohort study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5697-y"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/archotol.126.5.652","article-title":"Hypothyroidism After Treatment for Nonthyroid Head and Neck Cancer","volume":"126","author":"Sinard","year":"2000","journal-title":"Arch. Otolaryngol.-Head Neck Surg."},{"key":"ref_14","first-page":"11","article-title":"Hypothyroidism and Thyroiditis after Therapy for Hodgkin\u2019s Disease","volume":"109","author":"Keresztes","year":"2002","journal-title":"Acta Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.2005.05.0195","article-title":"White Race As a Risk Factor for Hypothyroidism After Treatment for Pediatric Hodgkin\u2019s Lymphoma","volume":"24","author":"Metzger","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1210\/er.2010-0003","article-title":"Exposing the Thyroid to Radiation: A Review of Its Current Extent, Risks, and Implications","volume":"31","author":"Sinnott","year":"2010","journal-title":"Endocr. Rev."},{"key":"ref_17","unstructured":"PDQ Pediatric Treatment Editorial tabkleBoard (2021). Late Effects of Treatment for Childhood Cancer (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries [Internet], National Cancer Institute."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/pbc.22082","article-title":"Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study","volume":"53","author":"Chow","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0360-3016(97)00117-X","article-title":"Hypothyroidism after external radiotherapy for head and neck cancer","volume":"39","author":"Tell","year":"1997","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3324\/haematol.2015.140053","article-title":"Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study","volume":"101","author":"Oudin","year":"2016","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1288\/00005537-198404000-00002","article-title":"Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of the head and neck","volume":"94","author":"Posner","year":"1984","journal-title":"Laryngoscope"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.seminoncol.2019.07.004","article-title":"Technological evolution of radiation treatment: Implications for clinical applications","volume":"46","author":"Pacelli","year":"2019","journal-title":"Semin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Barrett, A., Morris, S., Dobbs, J., and Roques, T. (2009). Practical Radiotherapy Planning, Taylor & Francis. [4th ed.].","DOI":"10.1201\/b13373"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.oraloncology.2018.08.018","article-title":"Revisiting the dose constraints for head and neck OARs in the current era of IMRT","volume":"86","author":"Brodin","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jjco\/hyt235","article-title":"Dose-volumetric Parameters for Predicting Hypothyroidism after Radiotherapy for Head and Neck Cancer","volume":"44","author":"Kim","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1748-717X-9-104","article-title":"V30 as a predictor for radiation-induced hypothyroidism: A dosimetric analysis in patients who received radiotherapy to the neck","volume":"9","author":"Akgun","year":"2014","journal-title":"Radiat Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/jrr\/rrv006","article-title":"The threshold of hypothyroidism after radiation therapy for head and neck cancer: A retrospective analysis of 116 cases","volume":"56","author":"Fujiwara","year":"2015","journal-title":"J. Radiat. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1002\/cam4.2574","article-title":"Thyroid dose-volume thresholds for the risk of radiation-related hypothyroidism in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy\u2014A single-institution study","volume":"8","author":"Huang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_30","unstructured":"American Cancer Society (2005). Cancer Facts and Figures 2005, American Cancer Society."},{"key":"ref_31","unstructured":"Harris, J.R., Lippman, M.E., Morrow, M., and Osborne, C.K. (2004). Diseases of the Breast, Lippincott Williams & Wilkins. [3rd ed.]."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0959-8049(00)00435-4","article-title":"Prognostic factors in breast cancer: The predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution","volume":"37","author":"Giardina","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2003.11.105","article-title":"Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer","volume":"21","author":"Olivotto","year":"2003","journal-title":"J Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chan, C.W.H., Law, B.M.H., So, W.K.W., Chow, K.M., and Waye, M.M.Y. (2017). Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112423"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","article-title":"Ki67 is a promising molecular target in the diagnosis of cancer (Review)","volume":"11","author":"Li","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.maturitas.2013.09.008","article-title":"Targeted cancer therapy\u2014Are the days of systemic chemotherapy numbered?","volume":"76","author":"Joo","year":"2013","journal-title":"Maturitas"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.5858\/arpa.2019-0205-RA","article-title":"Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2\/neu Evaluation","volume":"143","author":"Jorns","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_38","first-page":"1","article-title":"Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab","volume":"98","author":"Fujita","year":"2019","journal-title":"Oncology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10961","DOI":"10.1038\/s41598-019-47375-2","article-title":"Prognostic and predictive role of tumour -associated macrophages in HER2 positive breast cancer","volume":"9","author":"Honkanen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.18632\/oncotarget.27603","article-title":"Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting","volume":"11","author":"Montella","year":"2020","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ctrc.2016.03.005","article-title":"Activity of transtuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series","volume":"7","author":"Keith","year":"2016","journal-title":"Cancer Treat Commun."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hurvitz, S.A., Im, S., Lu, Y., Colleoni, M., Franke, F.A., Bardia, A., Harbeck, N., Chow, L., Sohn, J., and Lee, K.S. (2019, January 4). Phase III MONALEESA-7 trial of premenopausal patients with HR+\/HER2\u2212 advanced breast cancer treated with endocrine therapy \u00b1 ribociclib: Overall survival results. Proceedings of the 2019 ASCO Annual Meeting, Chicago, IL, USA. Abstract LBA1008.","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA1008"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2013MONARCH 2: A randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/00365519850186670","article-title":"Thyroid function in postmenopausal breast cancer patients treated with tamoxifen","volume":"58","author":"Anker","year":"1998","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/1097-0142(19861001)58:7<1422::AID-CNCR2820580707>3.0.CO;2-6","article-title":"The effect of tamoxifen therapy on thyroid function tests","volume":"58","author":"Gordon","year":"1986","journal-title":"Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00044011-200828100-00007","article-title":"Exemestane-Induced Subclinical Hypothyroidism","volume":"28","author":"Mazokopakis","year":"2008","journal-title":"Clin. Drug Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/08998280.2020.1786227","article-title":"Effect of chemoradiation on the size of the thyroid gland","volume":"33","author":"Rivas","year":"2020","journal-title":"Bayl. Univ. Med Cent. Proc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10549-014-3256-4","article-title":"Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01)","volume":"149","author":"Janssen","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet, 378, 1707\u20131716.","DOI":"10.1016\/S0140-6736(11)61629-2"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.radonc.2020.01.022","article-title":"Post-mastectomy radiotherapy is associated with improved overall survival in T3N0 patients who do not receive chemotherapy","volume":"145","author":"Almahariq","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ijrobp.2008.10.034","article-title":"Variability of target and normal structure delineation for breast-cancer radiotherapy: A RTOG multi-institutional and multi-observer study","volume":"73","author":"Li","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.radonc.2015.12.027","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1","volume":"118","author":"Offersen","year":"2016","journal-title":"Radiother Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/1754-9485.12804","article-title":"Contouring consensus guidelines in breast cancer radiotherapy: Comparison and systematic review of patterns of failure","volume":"63","author":"Gee","year":"2018","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_55","first-page":"139","article-title":"Thyroid Dysfunction Following Supraclavicular Irradiation in the Management of Carcinoma of the Breast","volume":"24","author":"Akurek","year":"2014","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bjc.1985.99","article-title":"Primary hypothyroidism in breast cancer patients with irradiated supraclavicular lymph nodes","volume":"51","author":"Nooyen","year":"1985","journal-title":"Br. J. Cancer"},{"key":"ref_57","first-page":"4577","article-title":"Thyroid Function after Postoperative Radiation Therapy in Patients with Breast Cancer","volume":"17","author":"Tukiendorf","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijrobp.2020.12.047","article-title":"Risk of Hypothyroidism in Women After Radiation Therapy for Breast Cancer","volume":"110","author":"Choi","year":"2021","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/acm2.12668","article-title":"Effect of dose constraint on the thyroid gland during locoregional intensity-modulated radiotherapy in breast cancer patients","volume":"20","author":"Haciislamoglu","year":"2019","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_60","first-page":"1","article-title":"Incidence of hypothyroidism after treatment for breast cancer\u2014A Danish matched cohort study","volume":"22","author":"Esen","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tipsro.2021.06.004","article-title":"Harmonization of breast cancer radiotherapy treatment planning in the Netherlands","volume":"19","author":"Hurkmans","year":"2021","journal-title":"Tech. Innov. Patient Support Radiat. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/cncr.23307","article-title":"Risk of hypothyroidism in older breast cancer patients treated with radiation","volume":"112","author":"Smith","year":"2008","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1007\/s12094-018-1875-7","article-title":"Evaluation of thyroid gland as an organ at risk after breast cancer radiotherapy: A systematic review and meta-analysis","volume":"20","author":"Darvish","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/ijc.IJC_607_18","article-title":"Should we consider thyroid gland as an organ at risk in carcinoma breast patients receiving adjuvant radiation by conformal technique? A single institute dosimetric study","volume":"57","author":"Madisetty","year":"2020","journal-title":"Indian J. Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/23\/5503\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:35:13Z","timestamp":1760168113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/23\/5503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":64,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["jcm10235503"],"URL":"https:\/\/doi.org\/10.3390\/jcm10235503","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]}}}